Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Drake

Showing results (401-410 of 456) with videos related to

Pageof 46
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|June 26, 2020
Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention TrialLauren M Hurwitz, Ibrahim Kulac, Berrak Gumuskaya, et al.
Prostate Cancer and Prostatic Diseases|November 2, 2016
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysisB Benzon, S G Zhao, M C Haffner, et al.
Journal for Immunotherapy of Cancer|November 9, 2016
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
The Prostate|June 6, 2015
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention TrialDanyelle A Winchester, Cathee Till, Phyllis J Goodman, et al.
Cancer Research|March 29, 2022
Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine TreatmentMarina Roy-Luzarraga, Louise E Reynolds, Beatriz de Luxán-Delgado, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2020
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate CancerAleksandar Z Obradovic, Matthew C Dallos, Marianna L Zahurak, et al.
The Journal of Clinical Investigation|February 5, 2020
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetZachary T Freeman, Thomas R Nirschl, Daniel H Hovelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid TumorsEmerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
Pageof 46

Showing results (401-410 of 456) with videos related to

Sort By:
Pageof 46
Cancer Prevention Research (Philadelphia, Pa.)|June 26, 2020
Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention TrialLauren M Hurwitz, Ibrahim Kulac, Berrak Gumuskaya, et al.
Prostate Cancer and Prostatic Diseases|November 2, 2016
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysisB Benzon, S G Zhao, M C Haffner, et al.
Journal for Immunotherapy of Cancer|November 9, 2016
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
The Prostate|June 6, 2015
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention TrialDanyelle A Winchester, Cathee Till, Phyllis J Goodman, et al.
Cancer Research|March 29, 2022
Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine TreatmentMarina Roy-Luzarraga, Louise E Reynolds, Beatriz de Luxán-Delgado, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2020
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate CancerAleksandar Z Obradovic, Matthew C Dallos, Marianna L Zahurak, et al.
The Journal of Clinical Investigation|February 5, 2020
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetZachary T Freeman, Thomas R Nirschl, Daniel H Hovelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid TumorsEmerson A Lim, Johanna C Bendell, Gerald S Falchook, et al.
Pageof 46